The abstract is read at the publisher; the summary is JClub's.
The “It’s All One Trial” master-protocol framework for stage 3 type 1 diabetes could cut total teplizumab development time by about 45 months.
- Why it matters: Disease-modifying therapy development for type 1 diabetes takes longer than other areas, and teplizumab’s confirmatory Phase III timeline is expected to take about a decade.
- What they did: The OT framework uses one continuously randomized population, one prospective statistical plan, and uninterrupted follow-up from early investigation through accelerated approval on an intermediate endpoint to later durability confirmation.
- The result: Compared with current practices for recent-onset type 1 diabetes, OT could reduce development time, increase use of participant data, and lessen repeated enrollment and study restarts.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.